Life changing therapy for osteo-arthritis patients: a biomarker lead approach



Osteoarthritis (OA) is the most common chronic joint disease and a leading cause of disability worldwide, affecting more than 300 million people. Current treatments only relieve OA symptoms but have no impact on the progression of the disease. OA-BIO represents the breakthrough development of two components that address an unmet need in advancing OA treatment (therapy and biomarkers). The consortium, composed of both industrial and academic partners, will join in their expertise to advance to phase II clinical trial 4P004, a novel first-in-class disease-modifying drug for OA, and to validate new OA imaging and liquid biopsy biomarkers for 4P004 efficacy determination and patient selection.


The aim of ARI within the OA_BIO project is to validate existing and identify novel liquid biopsy biomarkers from synovial fluid, blood, and urine samples for patient stratification and treatment response monitoring of 4P004, and to develop and validate novel cartilage regeneration biomarkers related with the efficacy of 4P004 for OA treatment.

  • Presentation
    Ciftci E, Grad S, Alini M, Li Z. Liraglutide's in vitro anti-inflammatory and regenerative properties on inflammatory human osteoarthritic chondrocytes- on behalf of the OA-BIO Consortium. 2023 EORS (oral)
  • Partner

    Berenbaum F (Prof), 4Moving Biotech, Saint-Antoine Hospital, Sorbonne University, Paris, France

    Tryfonidou M (Prof), Utrecht University, Utrecht, Netherlands

    Eckstein F (Prof), Chondrometrics GmbH, Ainring, Germany